Tarsus Pharmaceuticals, Inc Q4 Loss Decreases, Beats Estimates

(RTTNews) - Tarsus Pharmaceuticals, Inc (TARS) released Loss for fourth quarter that decreased from last year and beat the Street estimates.

The company's earnings totaled -$23.113 million, or -$0.60 per share. This compares with -$41.902 million, or -$1.31 per share, last year.

Analysts on average had expected the company to earn -$0.82 per share. Analysts' estimates typically exclude special items.

The company's revenue for the period rose 407.9% to $66.408 million from $13.076 million last year.

Tarsus Pharmaceuticals, Inc earnings at a glance (GAAP) :

-Earnings: -$23.113 Mln. vs. -$41.902 Mln. last year. -EPS: -$0.60 vs. -$1.31 last year. -Revenue: $66.408 Mln vs. $13.076 Mln last year.

The company’s fourth-quarter sales were driven by around 58,500 bottles of XDEMVY dispensed to patients, compared with approximately 15,700 bottles dispensed in the same period last year.

TARS was up by 9.24 percent at $49.75 in the pre-market trade on the Nasdaq.